Copyright
©The Author(s) 2017.
World J Clin Oncol. Jun 10, 2017; 8(3): 266-272
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.266
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.266
Table 4 Comparison of original hazard ratio and those from linear regression formula
Studies (by author) | n total (weight %) | RFS | OS | Assumption OS HR | ||||
HR | 95%CI | HR | 95%CI | |||||
Langer | 107 (9) | 0.78 | 0.46 | 1.31 | 0.77 | 0.42 | 1.4 | 0.87 |
Portier | 171 (15) | 0.66 | 0.45 | 0.96 | 0.73 | 0.48 | 1.1 | 0.75 |
Nordlinger1 | 342 (29) | 0.78 | 0.61 | 0.99 | 0.87 | 0.66 | 1.14 | 0.87 |
Ychou | 306 (26) | 0.89 | 0.66 | 1.19 | 1.09 | 0.72 | 1.64 | 0.97 |
Primrose | 236 (20) | 1.48 | 1.04 | 2.12 | 1.49 | 0.86 | 2.6 | 1.52 |
- Citation: Araujo RLC, Herman P, Riechelmann RP. Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review. World J Clin Oncol 2017; 8(3): 266-272
- URL: https://www.wjgnet.com/2218-4333/full/v8/i3/266.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i3.266